← Eichor
Condition: Dalpiciclib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Dalpiciclib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic
Phase 2 · 2 location(s) · Fujian Cancer Hospital · NCT07581834Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Canc
Phase 3 · 1 location(s) · Fudan University · NCT07615751Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and
Phase 2 · 1 location(s) · Shengjing Hospital · NCT05638594Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734Dalpiciclib in HR+/HER2- ABC
Phase N/A · 1 location(s) · RenJi Hospital · NCT06301438Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
Phase 2 · 1 location(s) · Tongji Hospital · NCT06149130A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Bre
Phase 3 · 1 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT07354022Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Phase 2 · 1 location(s) · Shengjing Hospital · NCT05228951A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
Phase 1 · 1 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT05628870Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
Phase N/A · 1 location(s) · Hebei Medical University Fourth Hospital · NCT05578053Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Peking University · NCT06684600Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07238881A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined Wit
Phase 3 · 2 location(s) · Risen (Suzhou) Pharma Tech Co., Ltd. · NCT07207070Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07492394ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06970912Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06341894Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy f
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT07467330Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07014410Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Can
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07610720Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06107673Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
Phase 1 · 1 location(s) · West China Hospital · NCT06109207
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.